TTNP - タイタン・ファ―マシュ―ティカルズ （Titan Pharmaceuticals Inc.） タイタン・ファ―マシュ―ティカルズTTNPのチャート
TTNPの企業情報
| symbol | TTNP |
|---|---|
| 会社名 | Titan Pharmaceuticals Inc (DE) （タイタン・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Titan Pharmaceuticals Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform ProNeura. The Company's drug candidate Probuphine is being developed for the long-term maintenance treatment of opioid dependence. Titan's ProNeura continuous drug delivery system consists of a small solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs the first one with a ropinirole implant for the treatment of Parkinson's disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism. タイタン・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。主に、重度な症状に対する治療薬の開発、製造、商品化に従事する。主要薬剤「Probuphine」はオピオイド依存症の治療後の血中濃度を6カ月維持するために使用される注入製剤。また、「Fanapt」は非定型抗精神病薬で、精神分裂症の治療に使用される。本社はカリフォルニア州サンフランシスコ。 Titan Pharmaceuticals, Inc., based in South San Francisco, CA, is a development stage company developing proprietary therapeutics with its ProNeura® long-term, continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes. |
| 本社所在地 | 400 Oyster Point Blvd. Suite 505 South San Francisco CA 94080 USA |
| 代表者氏名 | Marc Rubin マーク・ルービン |
| 代表者役職名 | Executive Chairman of the Board 取締役会長 |
| 電話番号 | +1 650-244-4990 |
| 設立年月日 | 33635 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | － |
| url | www.titanpharm.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ttnp |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -10.05200 |
| 終値（lastsale） | 0.21 |
| 時価総額（marketcap） | 4452786.24 |
| 時価総額 | 時価総額（百万ドル） 5.41857 |
| 売上高 | 売上高（百万ドル） 3.83000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 7.34557 |
| 当期純利益 | 当期純利益（百万ドル） -11.32500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Titan Pharmaceuticals Inc. revenues increased from $117K to $3.7M. Net loss decreased 46% to $3.5M. Revenues reflect License revenue increase from $117K to $3.7M. Lower net loss reflects Research and development - Balancing val decrease of 23% to $3.4M (expense) Stock-based Compensation in S&A decrease of 8% to $515K (expense). |
TTNPのテクニカル分析
TTNPのニュース
-3.69 Fall Turns Titan Pharmaceuticals Inc. (TTNP) Into A Losing Stock For Investors 2022/04/26 12:30:00 Marketing Sentinel
Titan Pharmaceuticals Inc. (NASDAQ:TTNP) has a beta value of 0.66 and has seen 1.1 million shares traded in the last trading session. The company, currently valued at $9.14M, closed the last trade at $0.74 per share which meant it lost -$0.02 on the day or -3.69% during that session. The TTNP stock price is -318.92% … -3.69 Fall Turns Titan Pharmaceuticals Inc. (TTNP) Into A Losing Stock For Investors Read More »
Opioids Agonist Drugs Market to Signify Healthy Growth by 2027 & COVID-19 impact | Titan pharmaceuticals, Egalet Corporation 2022/03/22 14:54:00 OpenPR
Opioids Agonist Drugs market research report is known as a methodical process of collecting and analyzing the information related to consumers, key pricing structure, competitors, market size, company profiles, target market, growth factors. It makes attentive to major players regarding
Titan Pharmaceuticals Raises $5.5M Via Equity 2022/02/02 17:27:17 Benzinga
Titan Pharmaceuticals Inc (NASDAQ: TTNP ) has announced a private placement of 3.37 million shares and 1.29 million pre-funded warrants. In addition, the Company has agreed to issue to the investor unregistered warrants to purchase up to an aggregate of 4.67 million shares. The combined offering price of each share or pre-funded warrant and Full story available on Benzinga.com
Titan Pharmaceuticals to raise $5.5M in stock and pre-funded warrant offering 2022/02/02 14:08:01 Seeking Alpha
Titan Pharmaceuticals (TTNP) trades 3.9% lower premarket after it entered into a securities purchase agreement with a single institutional investor to purchase 3.37M shares in a
Titan Pharmaceuticals Inc. (NASDAQ:TTNP) Shares Rebounded 9.65% From Their Lows But Can They Continue? 2021/12/24 13:30:00 Marketing Sentinel
In last trading session, Titan Pharmaceuticals Inc. (NASDAQ:TTNP) saw 0.69 million shares changing hands with its beta currently measuring 0.78. Companys recent per share price level of $1.14 trading at -$0.11 or -8.80% at ring of the bell on the day assigns it a market valuation of $11.19M. That closing price of TTNPs stock is Titan Pharmaceuticals Inc. (NASDAQ:TTNP) Shares Rebounded 9.65% From Their Lows But Can They Continue? Read More »
-3.69 Fall Turns Titan Pharmaceuticals Inc. (TTNP) Into A Losing Stock For Investors 2022/04/26 12:30:00 Marketing Sentinel
Titan Pharmaceuticals Inc. (NASDAQ:TTNP) has a beta value of 0.66 and has seen 1.1 million shares traded in the last trading session. The company, currently valued at $9.14M, closed the last trade at $0.74 per share which meant it lost -$0.02 on the day or -3.69% during that session. The TTNP stock price is -318.92% … -3.69 Fall Turns Titan Pharmaceuticals Inc. (TTNP) Into A Losing Stock For Investors Read More »
Opioids Agonist Drugs Market to Signify Healthy Growth by 2027 & COVID-19 impact | Titan pharmaceuticals, Egalet Corporation 2022/03/22 14:54:00 OpenPR
Opioids Agonist Drugs market research report is known as a methodical process of collecting and analyzing the information related to consumers, key pricing structure, competitors, market size, company profiles, target market, growth factors. It makes attentive to major players regarding
Titan Pharmaceuticals Raises $5.5M Via Equity 2022/02/02 17:27:17 Benzinga
Titan Pharmaceuticals Inc (NASDAQ: TTNP ) has announced a private placement of 3.37 million shares and 1.29 million pre-funded warrants. In addition, the Company has agreed to issue to the investor unregistered warrants to purchase up to an aggregate of 4.67 million shares. The combined offering price of each share or pre-funded warrant and Full story available on Benzinga.com
Titan Pharmaceuticals to raise $5.5M in stock and pre-funded warrant offering 2022/02/02 14:08:01 Seeking Alpha
Titan Pharmaceuticals (TTNP) trades 3.9% lower premarket after it entered into a securities purchase agreement with a single institutional investor to purchase 3.37M shares in a
Titan Pharmaceuticals Inc. (NASDAQ:TTNP) Shares Rebounded 9.65% From Their Lows But Can They Continue? 2021/12/24 13:30:00 Marketing Sentinel
In last trading session, Titan Pharmaceuticals Inc. (NASDAQ:TTNP) saw 0.69 million shares changing hands with its beta currently measuring 0.78. Companys recent per share price level of $1.14 trading at -$0.11 or -8.80% at ring of the bell on the day assigns it a market valuation of $11.19M. That closing price of TTNPs stock is Titan Pharmaceuticals Inc. (NASDAQ:TTNP) Shares Rebounded 9.65% From Their Lows But Can They Continue? Read More »
U.S. Opioids Market Huge Growth in Future Scope 2021-2028 | Purdue Pharma L.P., Titan Pharmaceuticals, Inc., Boehringer Ingelheim GmbH 2021/12/03 10:28:26 OpenPR
"U.S. Opioids Market, Drug Price, Sales and Clinical Trials Insight 2028 Report Highlights: U.S. Opioids Market Opportunity: > US$ 18,985.4 Million by 2028 U.S. Opioids Market Growth: 100% Absolute Growth Till 2028 U.S. Opioids Market Size Opportunity by Therapeutic Class Insight On Clinical
Opioid Use Disorder Market Forecast 2021-2028 | Opioid Use Disorder Industry Size, Share, Growth & Forecast 2021/12/01 10:44:00 Intrado Digital Media
Key Players covered in the Opioid Use Disorder Market Research report are Camurus Pfizer Inc., BioDelivery Sciences International Inc., TEVA PHARMACEUTICALS USA, INC, Orexo US, Inc., Indivior PLC, Hikma Pharmaceuticals, Mylan, Mallinckrodt. , Titan Pharmaceuticals Inc., Alkermes Key Players covered in the Opioid Use Disorder Market Research report are Camurus Pfizer Inc., BioDelivery Sciences International Inc., TEVA PHARMACEUTICALS USA, INC, Orexo US, Inc., Indivior PLC, Hikma Pharmaceuticals, Mylan, Mallinckrodt. , Titan Pharmaceuticals Inc., Alkermes
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Sees Significant Increase in Short Interest 2021/11/21 13:36:41 Transcript Daily
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) was the recipient of a large growth in short interest during the month of October. As of October 29th, there was short interest totalling 455,000 shares, a growth of 20.3% from the October 14th total of 378,200 shares. Based on an average daily volume of 185,700 shares, the days-to-cover ratio is []
Titan Pharmaceuticals (NASDAQ:TTNP) versus Rubius Therapeutics (NASDAQ:RUBY) Head to Head Review 2021/11/15 06:28:43 Dakota Financial News
Titan Pharmaceuticals (NASDAQ:TTNP) and Rubius Therapeutics (NASDAQ:RUBY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Insider and Institutional Ownership 5.9% of Titan Pharmaceuticals shares are owned by institutional investors. Comparatively, []